The main objective of this HORIZON 2020 project is to clinically validate a personalised medicine tool that predicts the most effective treatment option in myeloma patients. Currently, there are a range of single/combination novel agents and chemotherapy drugs available and in development for myeloma, the second most common type of blood cancer. As myeloma is a very heterogeneous disease, not every treatment is suitable for each patient. There is therefore an urgent need for a diagnostic tool that supports treatment decision-making in order to improve patient health outcomes, increase the value of new medicines to healthcare systems and to reduce healthcare costs.
SkylineDx will develop MMpredict, a microarray-test that can be used for genetic subtyping of MM patients. This tool should be able to determine the most effective treatment option for a patient by predicting their treatment response based on gene expression profiling (GEP).
The consortium aims to commercialise the MMpredictor as a personalised medicine tool that predicts the most effective treatment strategy for individual Multiple Myeloma (MM) patients.